Status: Recruiting
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical activity of ABX-001 administered intravenously (IV) alone (Part A) or co-administered with pembrolizumab (Part B) in participants with refractory/relapsed advanced solid tumors.
Participants needed: 27
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Abalos Therapeutics GmbHUpdated: Jan 16, 2026Locations: 5
Eligibility criteria
Participant must be capable of giving consent and at least 18 years of age at th... [+19]
Malignancy other than disease under study with the exception of those from which... [+31]